Neurobiological Predictors of Huntington's Disease (PREDICT-HD)

Study acronym: PREDICT-HD
StatusActive, Not Recruiting
PhaseNot specified
Started

Record status This record was last updated January 14, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: University of Iowa to Jordan Schultz
    • Primary and study completion dates: Jun 30, 2024 to Jun 30, 2025
    v27
  2. Primary and study completion dates: Mar 31, 2023 to Jun 30, 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v26
  3. Lead sponsor: Jane S. Paulsen to University of Iowav25
  4. Lead sponsor: University of Iowa to Jane S. Paulsenv24 Show 4 more changesShow less
    • Trial status: Active, Not Recruiting to Recruiting
    • Primary and study completion dates pushed to Mar 31, 2023
    • Enrollment target: 1500 to 1700
    • Study sites: 0 to 1
  5. Primary endpoints revised (3)
    • Study sites: 27 to 0
    • Primary completion date changed from estimate of Aug 2017 to Aug 31, 2017
    • Study completion date: Aug 2017 to Dec 2018
    v23
Show 21 earlier versionsHide 21 earlier versions
  1. Primary and study completion dates: Aug 2016 to Aug 2017v22
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 27 of 27 sites
    v21
  3. Primary and study completion dates: Aug 2015 to Aug 2016
    • Site contacts updated at 1 of 27 sites
    v20
  4. Primary and study completion dates: Aug 2014 to Aug 2015
    • Eligibility criteria expanded, about 22 words
    • Study description expanded, about 8 words
    • Site details revised at 27 of 27 sites
    v19
  5. Primary and study completion dates: Aug 2013 to Aug 2014v18
  6. Enrollment target: 1100 to 1500
    • Study sites: 32 to 27
    • Eligibility criteria revised
    • Study description shortened, about 1 word
    v17
  7. Re-verified, no change to tracked fieldsv16
  8. Site contacts updated at 5 of 32 sitesv15
  9. Re-verified, no change to tracked fieldsv14
  10. Site details revised at 1 of 32 sitesv13
  11. Enrollment target: 990 to 1100
    • Primary completion date: Aug 2013
    • Study completion date: Aug 2008 to Aug 2013
    • Site contacts updated at 7 of 32 sites
    v12
  12. Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS) to University of Iowa
    • Collaborators expanded, about 8 words
    v11
  13. Study completion date: Aug 2008
    • Site contacts updated at 1 of 32 sites
    v10
  14. Site contacts updated at 4 of 32 sitesv9
  15. Enrollment target: 925 to 990
    • Site contacts updated at 2 of 32 sites
    v8
  16. Enrollment target: 900 to 925v7
  17. Enrollment target: 650 to 900
    • Study sites: 25 to 32
    v6
  18. 3 versions Re-verified since Nov 7, 2005, no change to tracked fieldsv3-v5
  19. Site contacts updated at 3 of 25 sitesv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this trial is to study early brain and behavioral changes in people who have the gene expansion for Huntington's disease, but are currently healthy and have no symptoms.
Trial Details
NCT Number NCT00051324
Lead Sponsor Jordan Schultz
Collaborators: National Institute of Neurological Disorders and Stroke (NINDS)
Conditions
(from sponsor)		 Huntington Disease
Related terms Huntington Disease
Enrollment 1,700 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov